In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vertex Sells Productivity

Executive Summary

Intent on finding drug leads, Vertex constructed an integrated drug-discovery platform based on understanding the structures of biological targets and then using that understanding to construct complementary compounds and compound libraries more likely to produce lead drug candidates, not simply screening hits. Its extraordinary productivity has led it to adopt a risk-reducing, alliance model, quite unlike the bet-the-farm strategies of most of its peers. Instead of focusing on a few partnerships and a few drugs for its own commercialization, Vertex has spent its time maximizing the number of programs it can put into drug development, largely through partners. To make up for the value it sacrifices by foregoing full commercialization, as well as the risks that its partners might slow development of Vertex programs, it generally insists on full control of the discovery end of R&D as well as a higher-than-average proportion of the products' end sales. Multinationals have generally balked at such deals and so the majority of Vertex's partners have been mid-sized regional players willing to cede discovery responsibilities and a larger share of the profits. But Vertex's $800 million chemogenomics deal with Novartis changes the company's deal and strategic profile; Vertex has complete authority over discovery through phase II; Novartis has control over the later stage. The deal, and its size, effectively validates and defines the Vertex strategy. Still, Vertex's focus on the early side of R&D, with less apparent commitment to creating a product franchise, has hurt its valuation, particularly at a time when investors expect biotech companies to take full advantage of at least some of the products they create.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts